Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD)

Christine Podrini, Michela Borghesan, Azzura Greco, Valerio Pazienza, Gianluigi Mazzoccoli, Manlio Vinciguerra

Research output: Contribution to journalArticlepeer-review

Abstract

Non-alcoholic fatty liver disease (NAFLD), an accumulation of intra-hepatic triglycerides that is often considered the hepatic manifestation of insulin resistance, is the most common cause of chronic liver disease in the Western countries with up to one third of the population affected. NAFLD is a spectrum of disturbances that encompasses various degrees of liver damage ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). NASH is characterized by hepatocellular injury/inflammation with or without fibrosis. The individuals with NAFLD develop NASH in 10% of the cases, and are also at risk of developing hepatocellular carcinoma (HCC). Epigenetic mechanisms of nuclear chromatin remodeling, such as DNA methylation, post-translational modifications of histones, and incorporation of histone variants into the chromatin are increasingly recognized as crucial factors in the pathophysiology of NAFLD. NAFLD is often accompanied by oxidative stress: reactive oxygen species (ROS) are implicated in altered reduction/oxidation (redox) reactions that attack cellular macromolecules and are detected in the liver of patients and animal models of NAFLD. In this review, we summarize recent knowledge advancements in the hepatic epigenetic and redox mechanisms, and their possible links, involved in the pathogenesis and treatment of NAFLD.

Original languageEnglish
Pages (from-to)2737-2746
Number of pages10
JournalCurrent Pharmaceutical Design
Volume19
Issue number15
DOIs
Publication statusPublished - 2013

Keywords

  • Epigenetics
  • Non-alcoholic fatty liver disease (NAFLD)
  • Oxidative stress

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Fingerprint

Dive into the research topics of 'Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD)'. Together they form a unique fingerprint.

Cite this